RxDoctor Payments Data

John Morris, MD

Nephrology · Memphis, TNNPI 1235185315

Payments from drug & device makers

$2,771in general payments, 2019–2025

Across 37 payments — averaging $74.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vantive US Healthcare LLC$848
  • Travere Therapeutics, Inc.$452
  • Otsuka America Pharmaceutical, Inc.$287
  • Baxter Healthcare$276
  • Abbott$239
  • Mallinckrodt Hospital Products Inc.$150
  • plus $519 from 5 others

What the payments were for

  • Travel & lodging$57221%
  • Food & beverage$1,97871%
  • Education$2208%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,771 in reported general payments places this provider in the 65th percentile of 229 nephrology providers in Tennessee.

See all nephrology providers in Tennessee

Medicare billing

Part B allowed, 2024
$553,113
Medicare patients
561
Services billed
8,747

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JynarqueTolvaptan24$474,562
Thiola EcTiopronin12$145,458
FarxigaDapagliflozin Propanediol48$55,087
JardianceEmpagliflozin21$31,708
MyrbetriqMirabegron12$9,927
Potassium Citrate ErPotassium Citrate30$7,244
Sevelamer Carbonate22$6,241
Calcitriol131$1,691
Febuxostat12$1,238
Tamsulosin Hcl87$1,234
Furosemide159$1,233
Potassium Chloride36$1,232
Calcium Acetate19$1,144
Rosuvastatin Calcium42$933
Metoprolol Succinate43$698

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Jynarque$287$474,56224 claims
AstraZenecaFarxiga$115$55,08748 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 229 nephrology providers in Tennessee.

Other nephrology in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →